- Home
- UCAR vs MBRX Comparison
UCAR vs MBRX Comparison
Compare UCAR & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- MBRX
- Stock Information
- Founded
- UCAR 2013
- MBRX 2015
- Country
- UCAR China
- MBRX United States
- Employees
- UCAR 80
- MBRX N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- MBRX Health Care
- Exchange
- UCAR Nasdaq
- MBRX Nasdaq
- Market Cap
- UCAR 13.3M
- MBRX 14.7M
- IPO Year
- UCAR 2023
- MBRX 2016
- Fundamental
- Price
- UCAR $3.15
- MBRX $0.69
- Analyst Decision
- UCAR
- MBRX Strong Buy
- Analyst Count
- UCAR 0
- MBRX 2
- Target Price
- UCAR N/A
- MBRX $6.00
- AVG Volume (30 Days)
- UCAR 19.1K
- MBRX 967.8K
- Earning Date
- UCAR 06-17-2025
- MBRX 05-13-2025
- Dividend Yield
- UCAR N/A
- MBRX N/A
- EPS Growth
- UCAR N/A
- MBRX N/A
- EPS
- UCAR N/A
- MBRX N/A
- Revenue
- UCAR $6,067,871.00
- MBRX N/A
- Revenue This Year
- UCAR N/A
- MBRX N/A
- Revenue Next Year
- UCAR N/A
- MBRX N/A
- P/E Ratio
- UCAR N/A
- MBRX N/A
- Revenue Growth
- UCAR 124.09
- MBRX N/A
- 52 Week Low
- UCAR $2.30
- MBRX $0.40
- 52 Week High
- UCAR $9.43
- MBRX $4.90
- Technical
- Relative Strength Index (RSI)
- UCAR 59.14
- MBRX 28.91
- Support Level
- UCAR $3.05
- MBRX $0.62
- Resistance Level
- UCAR $3.41
- MBRX $0.93
- Average True Range (ATR)
- UCAR 0.22
- MBRX 0.07
- MACD
- UCAR 0.01
- MBRX -0.03
- Stochastic Oscillator
- UCAR 69.23
- MBRX 9.64
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.